Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

ABACUS MEDICINE A/S - Group Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmarkIFRS Analyst: XBRLDenmarkIFRS

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   2.6% 1.3% 3.1% 2.5% 1.5% 1.6% 4.1% 4.1%   Credit score (0-100)   63 80 56 61 75 74 49 49   Credit rating   BBB A BBB BBB A A BBB BBB   Credit limit (mEUR)   0.0 0.6 0.0 0.0 0.3 0.3 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mEUR)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   332 421 664 941 1,024 1,210 1,210 1,210   Gross profit   32.6 39.3 47.2 58.6 79.1 114 0.0 0.0   EBITDA   12.6 10.6 12.5 16.6 26.2 47.5 0.0 0.0   EBIT   9.9 5.4 5.3 6.4 14.7 35.6 0.0 0.0   Pre-tax profit (PTP)   7.3 2.6 1.3 2.1 8.5 25.7 0.0 0.0   Net earnings   5.4 0.8 0.4 0.4 5.8 20.0 0.0 0.0   Pre-tax profit without non-rec. items   7.3 2.6 1.3 2.1 8.5 25.7 0.0 0.0     See the entire income statement 1.0 Balance sheet (mEUR)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   3.0 5.9 16.7 20.8 19.9 18.2 0.0 0.0   Shareholders equity total   14.4 51.6 53.0 54.6 61.0 80.9 81.0 81.0   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   97.2 127 220 216 233 319 81.0 81.0   Net Debt   -1.3 -2.0 -0.2 -3.9 -10.0 -3.3 -44.4 -44.4     See the entire balance sheet 1.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   332 421 664 941 1,024 1,210 1,210 1,210   Net sales growth   31.3% 26.8% 57.4% 41.8% 8.8% 18.2% 0.0% 0.0%   Gross profit   32.6 39.3 47.2 58.6 79.1 114 0.0 0.0   Gross profit growth   11.3% 20.6% 20.0% 24.1% 35.0% 44.4% -100.0% 0.0%   Employees   0 0 0 0 0 241 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   97 127 220 216 233 319 81 81   Balance sheet change%   72.1% 30.6% 72.9% -1.8% 8.1% 36.9% -74.6% 0.0%   Added value   12.6 10.6 12.5 16.6 24.9 47.5 0.0 0.0   Added value %   3.8% 2.5% 1.9% 1.8% 2.4% 3.9% 0.0% 0.0%   Investments   2 2 16 -4 -12 -10 -18 0   Net sales trend   2.0 3.0 4.0 5.0 5.0 5.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   3.8% 2.5% 1.9% 1.8% 2.6% 3.9% 0.0% 0.0%   EBIT %   3.0% 1.3% 0.8% 0.7% 1.4% 2.9% 0.0% 0.0%   EBIT to gross profit (%)   30.3% 13.7% 11.3% 10.9% 18.6% 31.2% 0.0% 0.0%   Net Earnings %   1.6% 0.2% 0.1% 0.0% 0.6% 1.7% 0.0% 0.0%   Profit before depreciation and extraordinary items %   2.4% 1.4% 1.1% 1.1% 1.7% 2.6% 0.0% 0.0%   Pre tax profit less extraordinaries %   2.2% 0.6% 0.2% 0.2% 0.8% 2.1% 0.0% 0.0%   ROA %   13.0% 5.0% 3.1% 3.0% 6.5% 14.6% 0.0% 0.0%   ROI %   72.0% 14.7% 8.7% 9.3% 19.4% 46.3% 0.0% 0.0%   ROE %   44.5% 2.5% 0.8% 0.8% 10.1% 28.3% 0.0% 0.0%   1.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   14.8% 40.7% 24.2% 25.3% 26.2% 25.4% 100.0% 100.0%   Relative indebtedness %   24.9% 17.9% 25.1% 17.1% 16.8% 19.7% 0.0% 0.0%   Relative net indebtedness %   24.5% 17.4% 25.1% 16.7% 15.8% 19.4% -3.7% -3.7%   Net int. bear. debt to EBITDA, %   -10.7% -18.5% -1.7% -23.5% -38.1% -6.9% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.3 0.5 0.4 0.3 0.4 0.3 0.0 0.0   Current Ratio   1.0 1.4 1.1 1.1 1.1 1.1 0.0 0.0   Cash and cash equivalent   1.3 2.0 0.2 3.9 10.0 3.3 0.0 0.0   1.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   20.9 27.9 32.9 15.6 17.1 16.8 0.0 0.0   Trade creditors turnover (days)   510.0 716.6 1,123.4 1,063.1 1,161.9 1,603.0 0.0 0.0   Current assets / Net sales %   24.1% 24.2% 25.4% 16.8% 17.1% 21.4% 3.7% 3.7%   Net working capital   -1.0 31.3 10.2 13.4 16.7 29.7 0.0 0.0   Net working capital %   -0.3% 7.4% 1.5% 1.4% 1.6% 2.5% 0.0% 0.0%   1.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 5 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0